Cancer Genetics Signs Clinical Trial Pact With Biotechs

DNA-based diagnostics firm Cancer Genetics has signed on to perform testing for six clinical trials of biotech companies working on blood-born cancers. The contracts will net upwards of $2.5 million, the Rutherford, N.J., company said.

The company will use its comprehensive testing and biomarker analysis capabilities to focus on chronic lymphocytic leukemia, diffuse large B-cell lymphoma and T-cell lymphomas. The studies are already underway or will begin this quarter, CGI said.

CGI offers exclusive next-generation sequencing panels and microarray technology, which help to provide genomic assessment of cancers, according to the firm. The company’s tests and services have been used to assess patient compatibility for trials, monitor patient progress and genomic response and measure response to both single-agent and combination based therapeutic trials, the company added.

CGI recently launched FocusCCL, a targeted NGS-based panel for chronic lymphocytic leukemia that assesses seven genes with clinical relevance for prognosis, disease management and treatment selection.

The names of the biotech firms weren’t disclosed. — Kellen Owings